You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Oncology
Aro Biotherapeutics Names Cancer Biologist McMahon and Protein Structure and Design Expert Swanson to its Scientific Advisory Board
Login
Username:

Password:


Related Headlines

PAI Pharma acquires Nexus Pharmaceuticals

Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177

FDA grants Breakthrough Therapy designation to Clarity Pharmaceuticals' prostate cancer imaging agent

Guardant Health expands liquid biopsy test with AI-powered epigenomic applications

Nuvation Bio to present at Jefferies Global Healthcare Conference in London

Abbisko Therapeutics' PIMJETMI receives US FDA approval to treat tenosynovial giant cell tumour (TGCT)

Illumina expands MRD research portfolio with ultrasensitive sequencing technology

Photocure maintains 2028 Medicare coverage target for AssureMDx following CMS update

RYBREVANT FASPRO co-formulated with Halozyme's ENHANZE technology approved by US FDA in advanced head and neck cancer

Akeso publishes ivonescimab Phase II study results in Nature Medicine

INOVIO prices public offering of approximately USD75m

First patient dosed in Phase 1 trial of Transgene and BioInvent's BT-001 for rectal cancer

Elicera Therapeutics secures Chinese patent allowance for ELC-401

CHOSA Oncology signs US laboratory agreement for Platin-DRP commercialisation

BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026